AR041395A1 - Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla - Google Patents

Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla

Info

Publication number
AR041395A1
AR041395A1 ARP030103499A ARP030103499A AR041395A1 AR 041395 A1 AR041395 A1 AR 041395A1 AR P030103499 A ARP030103499 A AR P030103499A AR P030103499 A ARP030103499 A AR P030103499A AR 041395 A1 AR041395 A1 AR 041395A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
hydrogen
unsubstituted
cycloalkyl
Prior art date
Application number
ARP030103499A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR041395A1 publication Critical patent/AR041395A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP030103499A 2002-09-27 2003-09-25 Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla AR041395A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222493.9A GB0222493D0 (en) 2002-09-27 2002-09-27 Compounds

Publications (1)

Publication Number Publication Date
AR041395A1 true AR041395A1 (es) 2005-05-18

Family

ID=9944904

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103499A AR041395A1 (es) 2002-09-27 2003-09-25 Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla

Country Status (23)

Country Link
US (1) US20060240048A1 (fr)
EP (1) EP1565442B1 (fr)
JP (1) JP2006503845A (fr)
KR (1) KR20050071514A (fr)
CN (1) CN1703402A (fr)
AR (1) AR041395A1 (fr)
AT (1) ATE378317T1 (fr)
AU (1) AU2003268907A1 (fr)
BR (1) BR0314635A (fr)
CA (1) CA2500231A1 (fr)
DE (1) DE60317555T2 (fr)
ES (1) ES2294313T3 (fr)
GB (1) GB0222493D0 (fr)
IS (1) IS7809A (fr)
MA (1) MA27448A1 (fr)
MX (1) MXPA05003263A (fr)
NO (1) NO20052028L (fr)
NZ (1) NZ538943A (fr)
PL (1) PL375990A1 (fr)
RU (1) RU2005112752A (fr)
TW (1) TW200413321A (fr)
WO (1) WO2004029026A1 (fr)
ZA (1) ZA200502084B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492784A4 (fr) 2002-03-28 2006-03-29 Merck & Co Inc 2,3-diphenyl-pyridines substituees
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
SE0401343D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
DE602005010698D1 (de) 2004-06-09 2008-12-11 Glaxo Group Ltd Pyrrolopyridinderivate
AR055601A1 (es) * 2005-08-09 2007-08-29 Glaxo Group Ltd Compuestos derivados de imidazopiridina como ligandos de receptores canabinoides
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
WO2007118041A1 (fr) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Composés modulateurs du récepteur cb2
MX2009003316A (es) * 2006-10-04 2009-04-09 Hoffmann La Roche Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
WO2008063625A2 (fr) * 2006-11-20 2008-05-29 Adolor Corporation Composés pyridiniques et procédés relatifs à leur utilisation
AU2007347456B2 (en) * 2007-02-22 2011-10-06 Hemerus Medical, Llc A high capacity biological fluid filtration apparatus
CA2747801A1 (fr) * 2009-01-22 2010-07-29 Raqualia Pharma Inc. Composes de sulfone heterocycliques satures n-substitues ayant une activite agoniste du recepteur cb2
EP2415765A4 (fr) 2009-03-30 2012-08-15 Astellas Pharma Inc Composé pyrimidine
CA2772080C (fr) * 2009-08-24 2017-05-30 Neuralstem, Inc. Synthese d'une piperazine neurostimulatrice
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013048962A (ja) * 2012-12-12 2013-03-14 Hemerus Medical Llc 大容量の体液濾過装置
WO2018055640A1 (fr) * 2016-09-22 2018-03-29 Srf Limited Procédé de préparation de dérivés haloalkyle d'acide nicotinique
CN112262132A (zh) * 2018-06-27 2021-01-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型吡啶和吡嗪化合物
WO2020025574A1 (fr) 2018-08-03 2020-02-06 Bayer Aktiengesellschaft Procédé de préparation de 6-(haloalkyl)-2-halo-5-acylpyridines et d'intermédiaires pour ce procédé
EP3666759A1 (fr) 2018-12-10 2020-06-17 Bayer Aktiengesellschaft Préparation de 6-halo-2-(haloalkyl)-3-acylpyridines et leurs intermédiaires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands

Also Published As

Publication number Publication date
CN1703402A (zh) 2005-11-30
NO20052028L (no) 2005-06-03
MA27448A1 (fr) 2005-07-01
WO2004029026A1 (fr) 2004-04-08
DE60317555T2 (de) 2008-10-23
TW200413321A (en) 2004-08-01
US20060240048A1 (en) 2006-10-26
GB0222493D0 (en) 2002-11-06
DE60317555D1 (de) 2007-12-27
EP1565442B1 (fr) 2007-11-14
MXPA05003263A (es) 2005-07-05
BR0314635A (pt) 2005-08-02
AU2003268907A1 (en) 2004-04-19
CA2500231A1 (fr) 2004-04-08
JP2006503845A (ja) 2006-02-02
ATE378317T1 (de) 2007-11-15
ZA200502084B (en) 2006-02-22
ES2294313T3 (es) 2008-04-01
IS7809A (is) 2005-04-19
EP1565442A1 (fr) 2005-08-24
NZ538943A (en) 2007-01-26
RU2005112752A (ru) 2006-01-20
KR20050071514A (ko) 2005-07-07
PL375990A1 (en) 2005-12-12

Similar Documents

Publication Publication Date Title
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
AR033306A1 (es) Compuestos
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
CY1105035T1 (el) Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες
PE20030226A1 (es) Compuestos arilicos sustituidos con quinuclidinas para el tratamiento de enfermedades
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
AR042691A1 (es) Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas.
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR065863A1 (es) Derivados de imidazolidinona
AR048717A1 (es) Derivados de acido hexenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
PE20090592A1 (es) Nuevos derivados de piperazina-amida
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR058257A1 (es) Derivados de 8-azabiciclo[3.2.1]octano. composiciones farmaceuticas.
AR017127A1 (es) Nuevos compuestos de piperazina y piperidina, un metodo para su preparacion, composiciones farmaceuticas que las contienen, metodos para prepararlas y nuevos compuestos intermedios para dicho metodo.
PE20040531A1 (es) Derivados de isoindolona, proceso de preparacion, compuestos intermedios de este proceso y composiciones farmaceuticas que los contienen
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal